

13/01/2026

## Treatment of Cancers

**Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	55
1.2 Apalutamide (Erleada)	24
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	5
1.4 Darolutamide (Nubeqa)	20
1.5 Enzalutamide (Xtandi)	169
1.6 Talazoparib (Talzenna)	<5
1.7 Docetaxel	73
1.8 Relugolix (Orgovyx, Ryeqo)	<5
1.9 Olaparib (Lynparza)	21

**Use of <5 (less than five):** We are unable to provide an exact figure - exempt from release under Section 40(2) of the Freedom of Information Act - Personal Information relating to a third party, as the small numbers involved could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulation 2018.

**Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?**

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	16
2.2 Olaparib (Lynparza) for prostate cancer	<5

13/01/2026

2.3 Talazoparib (Talzenna) for prostate cancer	<5
2.4 Relugolix (Orgovyx) for prostate cancer	<5

Q3. How many patients received their **first cycle** or **first dose** of the following products in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

Name of medicine	Number patients treated in <b>Cycle 1 or Dose 1</b>
3.1 Abiraterone (Zytiga or generic abiraterone)	13
3.2 Apalutamide (Erleada)	<5
3.3 Cabazitaxel (Jevtana or generic cabazitaxel)	<5
3.4 Darolutamide (Nubeqa)	<5
3.5 Enzalutamide (Xtandi)	26

Q4. How many patients were treated with the following combinations in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available? Please give **total** number of patients and number of patients receiving their **first dose** or **first cycle**.

Name of medicine	<b>Total</b> Number patients treated	Number patients received <b>cycle 1 or dose 1</b>
4.1 Darolutamide (Nubeqa) + Docetaxel	<5	<5
4.2 Darolutamide (Nubeqa)	20	<5
4.3 Olaparib (Lynparza) + Abiraterone	<5	<5

Q5. How many patients received the following products for **non-metastatic hormone sensitive prostate cancer** in the 3 months between 1st July 2025 to the end of September 2025, or latest 3-months for which data are available?

\*\*Of note figures are for all prostate cancer patients

Name of medicine	Number patients treated
5.1 Abiraterone	55
5.2 Enzalutamide	169

Q6a. How many patients with high grade epithelial stage III or IV **ovarian, fallopian tube or primary peritoneal cancer** were treated with **platinum**

13/01/2026

**chemotherapy** between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available? 86

Q6b. How many patients with high grade epithelial stage III or IV **ovarian, fallopian tube or primary peritoneal cancer** received **maintenance therapy** between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

This information is not available from our system and to provide it, would involve manual searches that would require more than eighteen hours to complete

Belfast Trust considers that the cost of retrieving the information would be above the 'Appropriate Limit', as defined by the Freedom of Information Act under Section 12. Section 12 of the Freedom of Information Act makes provision for public authorities to refuse requests for information where the cost of dealing with them would exceed the appropriate limit. The limit has been specified as £450 for public authorities such as Belfast Trust. This represents the cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

Q6c. How many patients were treated with **olaparib (Lynparza)** for the following types of cancer between 1st July 2025 and 30th September 2025, or latest 3-month period for which data is available?

Type of cancer	ICD-10 codes	Number of patients
a. Breast Cancer	C50* or D05	<5
b. Ovarian Cancer	C56* or C57* or C79.6 or C79.8 or C48.1 or C48.2	19
c. Prostate Cancer	C61*	<5

Q6d. How many patients were treated with olaparib (Lynparza) for the following indications and BlueTeq CDF codes between 1st Jul 2025 and 30th Sep 2025, or latest 3-month period for which data is available?

As above: This information is not available from our system and to provide it, would involve manual searches that would require more than eighteen hours to complete

BlueTeq CDF code	BlueTeq CDF description (copied from CDF List)	Number of patients
OLAP1a or OLAPb	Maintenance treatment in patients with high grade epithelial stage III or IV <b>ovarian, fallopian tube or primary peritoneal carcinoma who are in response following platinum-based FIRST line</b>	

13/01/2026

	<b><u>chemotherapy</u></b> AND have a deleterious or suspected deleterious germline and/or somatic BRCA mutation	
OLAP 2	Maintenance treatment in patients with high grade epithelial <b><u>ovarian, fallopian tube or primary peritoneal carcinoma</u></b> who HAVE a deleterious or suspected deleterious germline and/or somatic BRCA mutation and a recent FIRST RELAPSE of platinum-sensitive disease and are now <b><u>in response following a SECOND platinum- based chemotherapy</u></b>	
OLAP 3	Maintenance treatment in patients with high grade epithelial <b><u>ovarian, fallopian tube or primary peritoneal carcinoma</u></b> who have a deleterious or suspected deleterious germline and/or somatic BRCA mutation and a recent SECOND OR SUBSEQUENT relapse of platinum-sensitive disease and are now <b><u>in response following a THIRD OR SUBSEQUENT platinum-based chemotherapy</u></b>	
OLAP 4	Maintenance treatment in patients with high grade epithelial stage III or IV <b><u>ovarian, fallopian tube or primary peritoneal carcinoma</u></b> who are in response following platinum-based FIRST line chemotherapy AND whose cancer has a positive status for homologous recombination deficiency as defined by the presence of either a deleterious or suspected deleterious BRCA 1/2 germline and/or somatic mutation or genomic instability	
OLAP 5	Olaparib monotherapy as <b><u>adjuvant</u></b> treatment of high-risk <b><u>TRIPLE NEGATIVE early breast cancer</u></b> treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation	
OLAP 6	<b><u>Adjuvant</u></b> treatment of high-risk <b><u>HORMONE RECEPTOR POSITIVE HER 2 NEGATIVE early breast cancer</u></b> treated with neoadjuvant or adjuvant chemotherapy and definitive local therapy in patients with a deleterious or suspected deleterious germline BRCA mutation	
OLAP 7	Olaparib monotherapy for <b><u>metastatic castration-resistant prostate cancer</u></b> bearing germline and/or somatic <b><u>BRCA 1 or 2 mutations</u></b> in patients who have progressed following previous treatment with an androgen receptor targeted agent AND HAVE ALSO BEEN TREATED WITH DOCETAXEL	
OLAP 8	Olaparib monotherapy for <b><u>metastatic castration-resistant prostate cancer</u></b> bearing germline and/or somatic <b><u>BRCA 1 or 2 mutations</u></b> in patients who have progressed following previous treatment with an	

13/01/2026

	androgen receptor targeted agent AND HAVE NOT BEEN PREVIOUSLY TREATED WITH DOCETAXEL	
OLAP 9	<b><u>Olaparib + abiraterone</u></b> for the treatment of <b><u>metastatic hormone- relapsed (castrate-resistant) prostate cancer</u></b> in patients who are treatment naïve to androgen receptor inhibitors and in whom chemotherapy is not yet clinically indicated or appropriate	